What GRIN Therapeutics does

GRIN Therapeutics, Inc. is a clinical-stage biotechnology company developing precision therapeutics for rare, severe pediatric neurodevelopmental disorders. Founded in 2019 by Dr. Pierandrea Muglia after engagement with the GRIN patient community at the CFERV Conference on GRIN Variants at Emory University, the company is headquartered in New York City (230 Park Avenue, Suite 2830) and operates as an affiliate of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company. The company focuses on a single core asset, radiprodil, an investigational orally bioavailable selective negative allosteric modulator (NAM) of the GluN2B (NR2B) subunit of the NMDA receptor, which addresses dysregulated NMDA receptor activity underlying multiple genetically defined neurodevelopmental conditions.

Radiprodil is being developed for three indications: GRIN-related neurodevelopmental disorder (GRIN-NDD) caused by gain-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D genes; tuberous sclerosis complex (TSC); and focal cortical dysplasia type II (FCDII). The company is running three concurrent clinical programs: the Phase 3 Beeline pivotal trial in GRIN-NDD (first patient dosed January 2026 with global sites in the US, UK, and Europe through May 2026), the Phase 1b/2a Astroscape trial in TSC/FCDII (initiated October 2024), and an observational natural history study for GRIN-NDD. The Phase 1b/2a Honeycomb trial reported a median 86% reduction in countable motor seizure frequency in 15 patients with gain-of-function GRIN variants, supporting advancement to Phase 3. Radiprodil has received FDA Breakthrough Therapy, FDA Orphan Drug, FDA Rare Pediatric Disease, EMA PRIME, and EMA Orphan Drug designations.

GRIN Therapeutics is currently pre-revenue, with a forward revenue model dependent on pharmaceutical product sales following regulatory approval, supplemented by licensing arrangements. In May 2025, the company closed a $140 million Series D round co-led by Blackstone Life Sciences and Angelini Pharma, concurrently entering an exclusive licensing agreement with Angelini Pharma for radiprodil development and commercialization outside North America, with $50 million upfront and potential total deal value exceeding $500 million. The company operates with 11-50 employees, engages patients and providers primarily through patient advocacy partnerships (GRIN2B Foundation, CureGRIN, TSC Alliance, Epilepsy Foundation), trial recruitment and genetic testing partners (InformedDNA, GeneDx, Broad Institute GRIN Portal), and scientific congresses including AES and ILAE.

Name

GRIN Therapeutics

Legal name

GRIN Therapeutics, Inc.

Website

https://grintherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil, an oral selective GluN2B NMDA receptor negative allosteric modulator, for rare pediatric neurodevelopmental disorders including GRIN-NDD, tuberous sclerosis complex, and focal cortical dysplasia type II.

Ownership category

akta.pro rank

Product category

Rare Pediatric Neurodevelopmental Disorder Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Rare disease therapeutics
• Neurodevelopmental disorder treatments
• NMDA receptor modulators
• Pediatric epilepsy therapies
• Precision medicine biotechnology

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Development and Commercialization: GRIN Therapeutics is a clinical-stage biotechnology company developing radiprodil for rare neurodevelopmental disorders. Revenue will be generated through product sales following regulatory approval. The company secured $140 million in Series D funding and entered a licensing agreement with Angelini Pharma worth over $500 million in potential future payments for development and commercialization rights outside North America.

Go-to-market motion1 record

Marketing channels4 records

Core offering

GRIN Therapeutics is developing radiprodil, an investigational orally bioavailable selective negative allosteric modulator of the GluN2B (NR2B) subunit of the NMDA receptor, for the treatment of rare pediatric neurodevelopmental disorders including GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). The company is advancing radiprodil through a global Phase 3 clinical program (Beeline) supplemented by additional clinical studies (Honeycomb, Astroscape) and a natural history study, with future commercialization planned through specialty rare-disease pharmaceutical channels.

Product overview

GRIN Therapeutics is a clinical-stage biotechnology company developing a single core pharmaceutical product, radiprodil, an investigational negative allosteric modulator of the GluN2B NMDA receptor subunit. The company operates multiple clinical trial programs including the Phase 3 Beeline trial for GRIN-NDD, the Phase 1b/2a Honeycomb trial (completed), the Phase 1b/2a Astroscape trial for TSC and FCDII, and an observational Natural History Study for GRIN-NDD. The company does not offer a software platform or module-based products.

Differentiator

Problem solved

Functional benefit

Brands

• Honeycomb Trial: Phase 1b/2a clinical trial evaluating radiprodil in GRIN-NDD patients with gain-of-function variants.
• Beeline Trial
• Astroscape Trial

Products and services

• Radiprodil Investigational, orally bioavailable, selective negative allosteric modulator (NAM) of the GluN2B (NR2B) subunit of the NMDA receptor. Developed for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD) with gain-of-function variants in GRIN1, GRIN2A, GRIN2B, or GRIN2D, tuberous sclerosis complex (TSC), and focal cortical dysplasia type II (FCDII). It modulates excessive NMDA receptor activity without fully inhibiting the channel, targeting the underlying pathological mechanism rather than just symptoms.

Quantifiable outcome

• Median 86% reduction in countable motor seizure frequency in Phase 1b/2a Honeycomb trial patients with gain-of-function variants
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• Angelini PharmaflagshipOEM/ Whitelabel/ Licensing Partner · 27 May 2025Angelini Pharma entered into an exclusive licensing agreement with GRIN Therapeutics for the development and commercialization of radiprodil outside North America. Angelini Pharma paid $50 million upfront as part of the agreement, with potential total deal value exceeding $500 million in future payments. The partnership covers multiple neurodevelopmental disorders including GRIN-NDD, TSC, and FCDII.
• InformedDNAcoreStrategic or Co-development PartnerInformedDNA serves as GRIN Therapeutics' partner for clinical trial recruiting and genetic counseling services specifically for patients with GRIN-NDD in the United States. The partnership helps route patients to genetic variant characterization and clinical trial opportunities.
• Broad Institute (GRIN Portal)coreTechnology or IntegrationGRIN Therapeutics works with the Broad Institute's GRIN Portal, which allows patients diagnosed with GRIN-NDD to explore information about their specific GRIN variant. This resource supports variant characterization for clinical trial eligibility.
• CureSHANKminorStrategic or Co-development PartnerGRIN Therapeutics is a supporting sponsor of CureSHANK's Genetic Testing Action Day initiative, supporting efforts to raise awareness about genetic testing for patients with rare diseases and developmental disabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Epygenix Therapeutics: Emerging clinical-stage biotech developing precision therapies for rare epilepsies including Dravet syndrome and Lennox-Gastaut syndrome. Comparable as an early-stage rare epilepsy player focused on genetically defined populations.

Broad incumbents

• Lundbeck: Global pharmaceutical company specializing in brain diseases including rare neurology. Relevant given Board Chair Deborah Dunsire's prior leadership; represents a strategic potential acquirer or partner for radiprodil given deep rare neurology commercial capabilities.
• BioMarin Pharmaceutical: Established rare disease biopharma with multiple orphan therapies on market. Comparable as a scaled rare disease commercial model with experience launching and pricing orphan therapeutics across geographies.
• Jazz Pharmaceuticals: Specialty pharmaceutical company with a significant rare neurology franchise including Epidiolex for rare epilepsies. Comparable as an established player in rare pediatric neurology commercialization that could compete or partner in the same end markets.
• UCB (Zogenix): Global biopharma with a rare epilepsy franchise built around Fintepla (fenfluramine) for Dravet and Lennox-Gastaut syndromes following the Zogenix acquisition. Comparable as a major incumbent commercializing rare pediatric epilepsy therapies that overlap with GRIN's TSC and FCDII target populations.

Direct peers

• Marinus Pharmaceuticals: Develops ganaxolone for rare seizure disorders including CDKL5 deficiency disorder and tuberous sclerosis complex. Directly comparable given its focus on rare pediatric epilepsies and overlapping TSC indication with radiprodil.
• Taysha Gene Therapies: Clinical-stage gene therapy company focused on monogenic rare diseases of the central nervous system. Comparable target patient profile (rare genetic neurodevelopmental disorders) and development-stage risk profile.
• Praxis Precision Medicines: Clinical-stage precision medicine company developing therapies for genetic epilepsies and CNS disorders. Comparable in approach (genetically defined rare CNS populations) and stage of clinical development.
• Stoke Therapeutics: Develops antisense oligonucleotide (ASO) therapies for genetic diseases including Dravet syndrome and other rare neurodevelopmental disorders. Comparable as a rare pediatric neuro precision medicine company with mechanism-driven development.
• Ovid Therapeutics: Clinical-stage biotech developing therapeutics for rare neurodevelopmental disorders including CDKL5 deficiency disorder and Angelman syndrome. Directly comparable as a rare pediatric neurology-focused biotech with similar development-stage assets and patient advocacy-driven strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GRIN_tx
• LinkedInlinkedin.com/company/grin-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GRIN Therapeutics